ABSTRACT
Introduction: Number of kidney acute and chronic disease is increasing rapidly in the world and becoming the major cause of death even population employment capacity is invalid. Statistical report of Mongolian Ministry of Health last 5 years statistic kidney disease is in the 3rd of non contagious disease.Synthetic and chemical medicines used for this sort of disease would have side effects in some cases. Plants, animals and minerals biologically active substances, side effects need to produce new drugs, has attracted the attention of researchers. Goal: identifying pharmacology act of new granule medicine preparation. Materials and Ìethods: Experiment is on 4 kinds of 35 white rat, 150-280 gram WISTAR RAT. 5 rats from each kind. 1. Healthy group 2. Disease model group /Kanamycin+distilled water/ 3. Standard group / Kanamycin+nefromon/ 4. Experiment group / Kanamycin+ +new form of granule medicine/ Kidney disease model was created artificially kanamycin sulfate (Monodoev. A.J, Lameza.S.B, Bartonov. EA 1988) MDA is identified by an amount of concentration and method. (Stalinaya.I.D 1977) Result: Creatinine amount of disease model group of kidney illness created by kanamycin sulfate is compared with healthy group animals and 1.64 times, carbamide amount is 4.25 times, rest of the azotes 2.73 are increased and comparing the experiment group creatinine amount is 1.65 creatinine amount is 1.65 decreased comparing with disease model group. Conclution: When compound ingredients preparation creates experiment animal kanamycin sulfate oxidant dominates, intensify the kidney cell active, decrease the carbamide and creatinine and decrease the kidney cell necrosis. Key words: Kanamycin, Wistar rate, Iris Tenuifolia, Oxytropsis pseudoglandulosa, Ribes Diacanthum and Granule.
ABSTRACT
Foundation of the research: The issues of safety and qualified medicine industrial, supplyment andmaintenance is the counterpart of national security policy about any nations. Mongolia has been importingover 80% of domestic demand of medicine. New drugs have accessed into marked, and medicine distributersor suppliers, pharmacies have established as many, thus its generating the needs to improve the legal environfor to reach the new level of quality control, medicine suppliers structure and activities, then also to verifythe safety of imported or local medicine. May having formulize the requirements of medicine warehouse,remodify the standard of Medicine Supply Organization can be the first step to solve the problems whichMedicine Supply Organization has been facing. The purpose and goals of research work:Submitting following goals in the frame of the purpose to analyze the condition of the Medicine SupplyOrganization’s warehouse, study the foreign country’s GSP and utilize the standard instruction of medicinewarehouse by determine the method of access it into Mongolian bigger Medicine Supply Organization.The methodology: Have selected and incorporated with 5 top company which are operating as medicineimporter based on value of imported products for last 3 years and 3 The pharmaceutical wholesale centerwhich had lesser scope and totally means 8 companies. We used following methods such as observationstudy, open review survey, schematic and comparative study, method of interview and review anddocumentation method.Conclusion:1. However, that research involved The pharmaceutical wholesale center have reached 71% of therequirement of MNS 5530:2009 standard of Medicine Supply Organization and fitted in low risk categoryas 20% according with the risk assessment of State Specialized Inspection Agency, but was lower by68% than building construction standard and activities according with the GSP’s guidance.2. Have determine the solutions for resolvable factors which are unreached the requirements of GSP basedon the study of World Health Organization, European Union GSP requirements, Kazakhstan, Bulgaria,Germany and Russian by linked it with the condition of research involved organizations.3. Utilized the Mongolian medicine warehouse standard guidance.